BioCritica, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioCritica, Inc.
Adrenomed Treads A New Path In Septic Shock
German firm Adrenomed has received new funding to push its innovative antibody for septic shock further into development. The company talks to Scrip about how it works, and why it won’t allow the asset to be a victim of strategic decision making.
Sepsis Pipeline Could Be Resuscitated With Narrower Trials, Researchers Propose
Sepsis trials designed with narrower enrollment criteria could allow treatment effects to emerge, countering the “signal to noise” problem that has plagued late-stage trials in sepsis, researchers suggest.
Start-Up Quarterly Statistics, Q2 2011
Funding for biopharma start-ups nearly doubled from Q1 to Q2 2011, with a total of $251 million. The quarter saw increased investment in emerging markets, particularly in China. Biopharma start-ups scored many deals with Big Pharma, in several cases playing the role of licensee. And while M&A activity for the start-up set was limited to two deals, for each of those agreements the start-ups were the ones on the acquiring side scooping up assets from other companies.
Selected Start-Ups
In Vivo briefly describes these recently founded companies: BioCritica, Entericon, Epiomed Therapeutics, Radisens Diagnostics, Sapiens and Sova Pharmaceuticals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice